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Publication No._______

Sarah Elizabeth Swain, B.S.

Supervisory Professor: Laura E. Mitchell, PhD

It is widely accepted that hypoplastic left heart syndrome (HLHS), aortic valve
stenosis with or without bicuspid aortic valve (AS/BAV) and coarctation of the aorta (CoA)
occur in families more commonly with each other than with any other congenital heart
defect (CHD). Genetic counseling for CHDs is currently based on empiric risk estimates
derived from data collected on all types of CHDs between 1968 and 1990. Additionally,
for the specific group of defects described above, termed left-sided lesions, estimates are
available for sibling recurrence. Utilizing family history data from 757 probands recruited
between 1997 and 2007 from The Children’s Hospital of Philadelphia, this study reassessed
the pre/recurrence risks for LSLs specifically. Sibling pre/recurrence risks for HLHS
(5.5%, 95% CI: 3.1%-8.9%), CoA (4.0%, 95% CI: 2.1%-6.7%), and AS/BAV (6.0%, 95%
CI: 3.3%-9.8%) were higher than currently quoted risks based on sibling data for individual
LSLs. Additionally, the prevalence of BAV in 202, apparently unaffected, parents of 134
probands was assessed by echocardiography. BAV, which occurs at a frequency of 1% in
the general population, was found to occur in approximately 10% of parents of LSL
probands. Lastly, among affected first-degree relative pairs (i.e. siblings, parent-offspring),
the majority (65%-70%) were both affected with a LSL. Defect specific concordance rates
were highest for AS/BAV. Together, these findings suggest that over the past 20 years with
iv

changing diagnostic capabilities and environmental/maternal conditions (e.g. folic acid
fortification, increased maternal diabetes and obesity) recurrence risks may have increased,
as compared to current LSL specific risk estimates. Based on these risk estimate increases
and prior studies, a protocol for screening first-degree relatives of LSL probands should be
devised.
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INTRODUCTION
Every year an estimated 7.9 million children, or 6 percent of total births worldwide,
are born with a serious birth defect of genetic or partially genetic origin (Christianson,
Howson, & Modell, 2006). Hundreds of thousands more are born with serious birth defects
of post-conception origin. Congenital heart defects (CHD) are the most common birth
defect worldwide, followed by neural tube defects, hemoglobinopathies, Down Syndrome
and glucose-6-phosphate dehydrogenase deficiency (Christianson, et al., 2006).
Significant advances in diagnosis, cardiac care and surgery have dramatically
increased survival of individuals born with a CHD and there are now greater than one
million CHD survivors in the United States (Pierpont et al., 2007). As more individuals
with CHD reach reproductive age, questions about genetic contribution to disease and risk
of transmission have moved to the forefront. Although the precise causes of CHDs remain
largely unknown, they are thought to have a multifactorial inheritance pattern where both
genetic and environmental factors contribute to disease (Nora, Berg, & Nora, 1991).
CHDs are anatomically, clinically, epidemiologically and developmentally
heterogeneous (Botto, Lin, Riehle-Colarusso, Malik, & Correa, 2007). However,
subgroups of CHDs have been identified (Ferencz, Rubin, Loffredo, & Magee, 1993).
These subgroups are based on underlying developmental mechanisms, epidemiological
evidence and clinical considerations. One such subgroup encompasses defects of the left
side of the heart, termed left-sided obstructive lesions (LSLs). The Baltimore Washington
Infant Study clearly showed that LSLs, including hypoplastic left heart syndrome, aortic
valve stenosis and coarctation of the aorta occur in families much more commonly with
each other than with any other CHD (Boughman et al., 1987). In general, genetic
counseling for these CHDs is currently based on empiric risk estimates, derived from data
1

collected on all types of CHDs between 1968 and 1990. However, sibling risk estimates for
specific LSLs are available.
Definition of left-sided cardiac lesions
The LSLs account for 15-20% of CHDs and include hypoplastic left heart syndrome
(HLHS), coarctation of the aorta (CoA), aortic valve stenosis (AS), and bicuspid aortic
valve (BAV) (Towbin & Belmont, 2000). The various LSLs differ considerably with
respect to morbidity and mortality. BAV (i.e. an aortic valve with two rather than three
leaflets) is the most common cardiovascular malformation with an incidence of 1-2% in the
general population. BAV has been shown to occur with increased frequency in
asymptomatic parents and other first-degree relatives of probands with LSLs (Cripe,
Andelfinger, Martin, Shooner, & Benson, 2004; Loffredo et al., 2004; Ward, 2000).
Although BAV is often considered a benign lesion early in life, complications, including
aortic stenosis and/or insufficiency, infective endocarditis and aortic dilation and dissection,
can result in morbidity and mortality later in life (Cripe, et al., 2004; Ward, 2000). On the
other end of the spectrum, HLHS, a condition where the left side of the heart, including the
left ventricle, aorta, mitral valve and aortic valve, is severely underdeveloped is fatal in
infancy without surgical intervention.
BIRTH PREVALENCE
The birth prevalence of CHDs is 5 to 10 per 1000 live births (Oyen et al., 2009).
Approximately 40,000 children are born each year in the United States with a clinically
significant heart defect and at least another 40,000 are born annually with subclinical
malformations that result in heart disease later in life (Shieh & Srivastava, 2009). A
comparison of several studies conducted during the second half of the twentieth century
revealed a range of prevalence estimates from various populations and at different time
2

frames within the same population (Table 1). This range may be due to differing methods
of case identification and/or the evolution of diagnostic techniques, as well as
environmental and temporal variation.
Table 1. Prevalence of congenital heart defects in defined populations
Population

Cases/1000

Time Frame

Sweden, Gothenburg

6.4

1941-1950

USA, NIH Collaborative

7.7

1956-1965

USA, California-Kaiser

11.7

1960-1966

Denmark

6.1

1963-1973

USA, New England

2.1

1969-1974

1.9-10.8

1979-1982

European Collaborative

6.04

1986

Switzerland

4.0

1986

Japan

10.6

1985

EUROCAT

Adapted from Nora, et al., 1991

A study conducted using data collected by the Metropolitan Atlanta Congenital
Defects Program from 1968 to 1997 aimed to determine racial variations in the prevalence
of heart defects (Botto, Correa, & Erickson, 2001). Although this study found an overall
greater prevalence of CHDs in the black population, this increase was not observed for all
defect categories. For example, LSLs tended to occur more frequently in whites, whereas
peripheral pulmonary stenosis occurred more frequently in blacks (Table 2).
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Table 2. Prevalence of LSLs by race (per 10,000 births)
Whites

Blacks

Rate Ratio
RateBlacks/RateWhites

HLHS

1.96

2.24

1.14

Coarctation of the aorta

3.33

2.36

0.71

Aortic valve stenosis

1.32

0.49

0.38

Peripheral Pulmonary
Stenosis

4.1

8.0

2.18

Defect Type

Adapted from Botto, Correa, & Erickson, 2001

NORMAL AND ABNORMAL DEVELOPMENT OF THE CARDIOVASULAR
SYSTEM
In order to understand the left-sided cardiac defects, it is important to examine the
normal development of the heart. In LSLs, all the essential components of the heart are in
place but are malformed or not working properly.
Normal cardiovascular development
As described in The Developing Human, the primordial heart and vascular system
appear in the middle of the third week of gestation, and the cardiovascular system is the
first major system to function in the embryo (Moore & Persaud, 2003). Cardiac function at
this early stage is necessary because the rapid rate of growth in the embryo requires an
efficient system for acquiring oxygen and nutrients from maternal blood and disposing of
carbon dioxide and waste. Thus cardiac function must begin even as cardiac development
progresses.
The cardiovascular system has three main derivations; splanchnic mesoderm, paraxial
and lateral mesoderm, and neural crest cells. The earliest sign of the heart are paired
angioblastic cords in the cardiogenic mesoderm that appear during the third week. These
4

paired cords canalize to form thin heart tubes that subsequently fuse, beginning at the
cranial end and extending caudally, as lateral embryonic folding occurs. This primitive
heart begins to beat at 22 to 23 days gestation and blood flow begins during the fourth week
gestation.
With cell growth and proliferation, the heart tube starts to bend upon itself, forming a
U-shaped bulboventricular loop. As the primordial heart bending continues, the sinus
venosus and atrium come to lie dorsal to the truncus arteriosus, bulbus cordis and ventricle,
creating the correct anatomical position of the adult heart in which the atria lie dorsal to the
ventricles, pulmonary trunk and aorta.
Initially, circulation through the heart is an ebb and flow. However, by the end of the
fourth week, coordinated contractions result in unidirectional flow. Blood from the
embryo, developing placenta and umbilical vesicle enters the sinus venosus through three
paired veins. The flow, which is controlled by the sinuatrial valves, then travels to the
primordial atrium. It passes through the atrioventricular canals into the primordial
ventricle. When the ventricle contracts, blood is pumped through the bulbous cordis and
truncus arteriosus to the aortic sac. From the aortic sac, it is distributed to the pharyngeal
arch arteries and then passes into the dorsal aortas for distribution to the embryo, umbilical
vesicle and placenta.
Partitioning of the primordial heart, including partitioning of the atrioventicular canal,
primordial atrium and ventricle, begins around the middle of the fourth week and is
essentially complete by the end of the eighth week. Endocardial cushions form on the
dorsal and ventral surfaces of the atrioventricular canal. As the endocardial cushions
approach each other and fuse, the atrioventricular canal divides into right and left canals.
These canals function as atrioventricular valves and partially separate the primordial atrium
5

from the primordial ventricle. Concurrently, the common atrium is partitioned into left and
right atria by the formation and modification of the septum primum and the septum
secundum.
At the end of the fourth week, the division of the primordial ventricle is indicated by a
ridge, the muscular interventricular septum, in the floor of the ventricle. The partition is
complete at the end of the seventh week, when the endocardial cushions and conotruncal
ridges fuse. The membranous part of the interventricular septum is derived from an
extension of tissue from the endocardial cushion to the muscular interventricular septum.
This then merges with the aorticopulmonary septum, which divides the truncus arteriosus
into the pulmonary trunk and ascending aorta. When closure is complete, the pulmonary
trunk communicates with the right ventricle, while the aorta communicates with the left
ventricle.
At five weeks, the aorticopulmonary septum undergoes a spiraling, accounting for the
twisting of the pulmonary trunk around the ascending aorta. When this partition and
twisting are nearly complete, the pulmonic and aortic valves begin to develop from three
swellings of subendocardial tissue around the openings of the aorta and pulmonary trunk.
These swellings form three thin-walled cusps. The tricuspid and mitral valves are formed
similarly from proliferations of tissue around the atrioventricular canals.
In the normal adult heart, deoxygenated blood enters the right atrium through the
superior and inferior vena cava and moves to the right ventricle through the tricuspid valve
where it is then pumped to the lungs through the pulmonic valve and pulmonary arteries.
Oxygenated blood then returns to the heart via the pulmonary veins and enters the left
atrium; blood moves to the left ventricle via the mitral valve and is pumped through the
aortic valve and aorta to the rest of the body.
6

Development of left-sided lesions
The development of the left side of the heart and the aortic outflow tract may be
affected by obstruction and subsequent reduction in blood flow. Most cases of LSLs are
isolated defects. There are few known genetic syndromes characterized by LSLs and few
individuals with an LSL have a recognized genetic syndrome. This lack of knowledge has
made it difficult to elucidate the pathogenesis of LSLs.
Hypoplastic left heart syndrome (HLHS)
First described in 1952 by Lev, HLHS is the most severe LSL. It occurs when parts of
the left side of the heart, including the mitral valve, left ventricle, aortic valve and aorta, do
not develop completely. Before 1980, HLHS was deemed inoperable and was almost
always fatal in infancy with extremely rare cases of survival into childhood (Studer &
Justino, 2010). In patients with HLHS, the left side of the heart is unable to send enough
blood to the body such that the right side of the heart must maintain the circulation for both
the lungs and the body. Because the aorta and left ventricle are so underdeveloped, the
systemic circulation is dependent on a patent ductus arteriosus, a shunt allowing the mixed
oxygenated/unoxygenated blood to cross from the pulmonary artery to the aorta and be
pumped to the rest of the body.
It is generally believed that HLHS develops as a result of an embryonic alteration in
blood flow (Ferencz, Loffredo, Correa-Villasenor, & Wilson, 1997). Specifically, cardiac
morphogenesis is thought to require both intrinsic processes of pattern formation and
extrinsic forces of blood-flow mediated remodeling (Towbin & Belmont, 2000). As
intracardiac blood flow begins before ventricular septation is complete, it may play a role in
modeling the chambers of the heart (Ferencz, et al., 1997).
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Coarctation of the Aorta (CoA)
CoA is defined as a constriction in the aortic isthmus between the origin of the left
subclavian artery and the ductus arteriosis, resulting in flow obstruction. This lesion is the
most common anomaly of the aortic arch, occurring in 5-8% of children with CHDs
(O'Brien, 2010; Towbin & Belmont, 2000). The clinical presentation of CoA varies,
depending on the age of the patient and the severity of the obstruction, from systemic
hypertension to congestive heart failure. Often, femoral pulses will be weaker than brachial
pulses.
The underlying mechanism causing CoA is not entirely understood, however it may
involve an abnormality in the tissue arising from the fourth or sixth aortic arches or from
reduced blood flow in the aortic arch during development in utero (O'Brien, 2010).
Aortic Valve Malformations
The most common left ventricular outflow tract obstruction in the pediatric
population is valvular aortic stenosis (AS), which accounts for approximately three-quarters
of all LSLs (Kitchiner et al., 1994). The underlying abnormality of AS is most commonly
restricted leaflet motion of the aortic valve, resulting in obstruction to left ventricular
outflow (O'Brien, 2010). The most frequent etiology of restricted leaflet motion is a
bicuspid aortic valve (BAV), caused by fusion of two of the three valve leaflets. Studies
suggest that approximately 1% of the general population have BAV (Roberts, 1970). Some
neonates and infants with aortic valve malformations present with severely stenotic,
unicuspid aortic valves that require immediate intervention. Although most children with
BAV are asymptomatic, development aortic stenosis and/or regurgitation, infective
endocarditis and aortic dissection may occur later in life (O'Brien, 2010).
According to Towbin and Belmont (2000), the formation of the valve leaflets requires
8

transformation of a subset of endothelial cells of the endocardium into mesenchyme; when
this transformation goes awry, valvular malformations arise.

DIAGNOSIS, TREATMENT AND PROGNOSIS
Approximately one-third of congenital heart disease is considered critical or cyanotic
and requires surgery or cardiac catheterization to assure survival (Botto, et al., 2001).
Children with critical CHD are diagnosed using a variety of methods. Fetuses may be
diagnosed on a routine level II targeted anatomy ultrasound at 18-20 weeks gestation.
However, it is estimated that only 20-40% of cases of critical CHDs are diagnosed
prenatally (Montana et al., 1996). In newborns, the diagnosis may be made on physical
exam with findings of a murmur, tachypnea or cyanosis (Koppel & Mahle, 2010). These
findings, however, are not always present prior to hospital discharge at 48 hours of life.
Consequently, diagnosis may be delayed until the neonate demonstrates features of
cardiogenic shock, poor growth, poor feeding, respiratory distress or a murmur prompting a
diagnostic workup (Koppel & Mahle, 2010).
Noninvasive imaging has become the cornerstone for the diagnosis of CHDs. The
introduction of cardiac catheterization and echocardiography has greatly improved
diagnostic capabilities prior to surgical intervention (Phoon, Chun, & Srichai, 2010).
Currently, many techniques, such as x-ray, echocardiography, cardiac catheterization and
simple clinical observation, are used in the diagnosis of congenital heart defects.
While the spectrum of outcomes for LSLs is wide, most of the left-sided obstructive
lesions presenting in the neonate or infant require surgical correction. HLHS has a greater
than 95% mortality rate in the first month of life if left untreated. In contrast, AS/BAV is
frequently a progressive disorder with a risk of arrhythmia or sudden death and only 20% of
9

neonates require intervention (Wyszynski, Correa-Villaseñor, & Graham, 2010).
Before the advent of cardiac surgery in the mid-1940’s, fewer than 25% of infants
born with complex CHDs survived past their first year of life. Today, in the beginning of
the 21st century, over 90% of infants with CHDs are expected to live into adulthood (Wu &
Landzberg, 2010). Despite improvements in life expectancy, no adult survivors are ever
really cured of their disease. Often, one problem is traded for a new set of problems after
surgical repair or transplant, as evidenced by data showing that adult survivors of CHDs
have significantly higher utilization of health care services than their peers (Mackie, Pilote,
Ionescu-Ittu, Rahme, & Marelli, 2007).
Echocardiography
In 1954, Edler and Hertz first reported recordings of ultrasound reflections from the
heart. By the 1970’s, two-dimensional echocardiography was in widespread use and
revolutionized diagnostic abilities in pediatric cardiology (Phoon, et al., 2010). Rapid
improvement in the technology, the addition of color Doppler flow mapping, and the
introduction of transesophageal (as opposed to transthoracic) and fetal echocardiography
put ultrasound imaging in its current position as the primary diagnostic tool for both
children and adults with known or suspected heart disease.
An echocardiogram, or sonogram of the heart, employs standard ultrasound
techniques to image the heart and produce an accurate assessment of the velocity and
direction of blood flow using Doppler ultrasound. This technique allows for non-invasive
assessment of the size and shape of the heart, pumping capacity, evaluation of the valves,
abnormalities in the pattern of blood flow and any abnormal communication between the
left and right side of the heart. In addition to the myocardium, chambers and valvular
structures, this noninvasive technique also evaluates the outflow tracts, coronary arteries,
10

great arteries, aortic arch, systemic arteries and systemic and pulmonary veins (Phoon, et
al., 2010).
In assessing individuals with valve disease, echocardiography is the primary imaging
modality used both for initial assessment and for long-term follow-up. Information
regarding valve structure and function, cardiac chamber size, wall thickness, and ventricular
function can be readily obtained and utilized to assess the severity of valve disease (Shah,
2010). For quality echocardiograms, it is essential to obtain the best possible images and
highly skilled interpretation based on training, experience and knowledge (Phoon, et al.,
2010). In some instances, body habitus or the presence of coexisting lung disease may
result in suboptimal studies, which are difficult to read (Shah, 2010).
As recently reviewed by O’Brien (2010), 2-D echocardiography is an excellent
method of evaluating the morphology of the aortic valve. The number of leaflets, whether
or not these leaflets are partially or completely fused, the size of the leaflets and thickening
of the leaflets are all examined from the parasternal short axis view. The dimension of the
aortic valve annulus and leaflet mobility is best demonstrated from the parasternal long axis
view. Color Doppler will reveal flow turbulence and aortic regurgitation.
Costs
CHDs are a heterogeneous group of serious birth defects that contribute to half of all
infant deaths each year and one-third of hospitalizations due to congenital anomalies in the
United States (Rosano, Botto, Botting, & Mastroiacovo, 2000). The cost of CHDs
encompass direct costs of healthcare as well as indirect costs of reduced economic
productivity of individuals with a CHD and reduced productivity of their caregivers. The
indirect costs are generally difficult to quantify and therefore, many studies focus only on
the direct costs with the acknowledgement that the true overall cost is likely greater than
11

that measured. An analysis conducted using data available through HCUPNet, the online
search tool for all Health Care Cost Utilization Project databases including the Nationwide
Inpatient Sample (NIS), found that the mean cost of healthcare for a child with CHD is 25
times greater than those for a child with no CHD (Boulet, Grosse, Riehle-Colarusso, &
Correa-Villaseñor, 2010).
Genetic Counseling
Genetic counseling, as defined by the National Society of Genetic Counselors, is a
process that helps people “understand and adapt to the medical, psychological, and familial
implications of the genetic contributions to disease” (Resta, 2006). Questions for genetic
professionals will arise no matter when a CHD is diagnosed, whether in a fetus, toddler, or
adult. Parents and patients will have questions regarding how/why this happened and will
wonder whether it will happen again. They may think about ways they can prevent this in
the future and the impact it will have on their own and/or their child’s life. Genetic
counseling for CHDs requires an understanding of the cardiac anatomy and the mechanism
of the defect; the ability to identify associated anomalies or syndromes; delineation of a
careful family history for risk assessment and ascertainment of other affected family
members; and information regarding the options for prenatal diagnosis (Lin & Garver,
1988).
Prenatal diagnosis for CHDs is steadily improving in frequency and accuracy. The
detection of a CHD may appear on a level I ultrasound as part of the general survey for
birth defects, pregnancy dates and placental exam. Later in pregnancy, the CHD may be
detected on the level II targeted anatomy scan conducted between 18-20 weeks gestation.
If a cardiac abnormality is suspected on ultrasound, follow-up with fetal echocardiography
will often be recommended. One study found that among infants undergoing cardiac
12

surgery, 57% had been diagnosed prenatally by fetal echocardiography (Mohan, Kleinman,
& Kern, 2005).
Another role of a genetic professional is emotional support for the individual and/or
parents of a fetus or child with a CHD. Because CHDs are often an isolated, internal
malformation, as opposed to an externally visible defect, there may be a tendency to
underestimate the impact on the family (Lin & Garver, 1988). Families should be
empowered with the tools to access the language, information, emotional and peer support
necessary to become active members in their child’s care and decision-making
conversations.

ETIOLOGY AND RISK FACTORS
Hypothesized etiologies
A multifactorial etiology, with environmental and genetic factors playing important
roles, is the most widely accepted hypothesis for the etiology of CHDs. It is well known
that environmental exposures during fetal development, such as maternal infections,
diabetes, and certain medications, increase the risk of CHDs. Further, the association of
CHDs with chromosome abnormalities and single-gene disorders demonstrates the
influence of genetic factors. Although the majority of CHD cases are non-syndromic, there
is evidence that these conditions aggregate within families and thus are likely to involve
genetic factors.
Evidence for genetic etiology
Pedigrees with more than one family member affected with a CHD appeared very
sporadically in the literature until the first large scale studies were undertaken in the 1950s
(Nora, et al., 1991). However, over the past 60 years, many studies have attempted to
13

quantify the risks conferred by a family history of CHD and environmental exposures.
Most studies support a multifactorial origin for CHDs in which a parent passes on a genetic
predisposition to disease and disease only manifests in individuals whose susceptibility
exceeds a threshold value (Shieh & Srivastava, 2009).
Between 1968 and 1990, 16 studies were conducted in an attempt to determine
recurrence of any congenital cardiac defect as well as recurrence of specific subtypes of
CHDs in the relatives of affected individuals (Anderson, 1976; Boughman, et al., 1987; W.
Fuhrmann, 1968; Walter Fuhrmann & Vogel, 1969; Jorgensen, Beuren, & Stoermer, 1971;
Mori, Ando, & Takao, 1973; Morris, Outcalt, & Menashe, 1990; Nora, 1968; Nora & Nora,
1978, 1988; Pierpont, Gobel, Moller, & Edwards, 1988; Sanchez-Cascos, 1978;
Williamson, 1969; Zoethout, Carter, & Carter, 1964). Nora, Berg, and Nora (1991),
combined risk estimates of these published data and generated the recurrence risks for
specific cardiac defects that are used today when counseling families (Table 3). Based on
these data the sibling recurrence risk for HLHS is quoted at 3%, while for CoA and AS this
risk is estimated at 2%. Using these same combined risk estimates, Nora, Berg, and Nora
(1991) reported a higher offspring recurrence risk for AS (5-18%) and CoA (3-4%).
Table 3. Recurrence risks in sibs for any congenital heart defect: data published
during two decades from European and North American populations
Proband Defect
Ventricular septal defect
Hypoplastic left heart
Patent ductus
Atrial septal defect
Endocardial cusion defect
Tetralogy of Fallot
Pulmonary stenosis
Coarctation of aorta
Aortic stenosis
Transposition

1968-1990
Risk(%)
3.2
3.2
3.1
2.7
2.5
2.4
2.2
2.1
2.0
1.4

Adapted from Nora, Berg, and Nora (1991)
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Findings from a pilot study of HLHS showed that the first-degree relatives of HLHS
probands have an increased risk for subclinical cardiac defects. Further, this study
demonstrated that HLHS, CoA and AS are more likely to co-occur with each other within a
family than they are to co-occur with other CHDs (Brenner, Berg, Schneider, Clark, &
Boughman, 1989). This suggests that these three conditions are more closely related to
each other than they are to other CHDs.
Left-sided lesions and subclinical BAV
Several groups have proposed that BAV represents a reduced or mild expression of
the more severe forms of LSLs, such as HLHS, and have sought to determine the
prevalence of BAV in the first-degree relatives of probands with LSLs. In 1989, Brenner
et. al. performed echocardiograms on 41 first degree relatives of 11 children with HLHS
and observed 5 of 41 (12%) with previously unrecognized BAV. Using a larger cohort,
Huntington et al performed echocardiograms on 186 first degree relatives of 30 adults with
BAV and found 17 of 186 (9%) to have previously unidentified BAV (Huntington, Hunter,
& Chan, 1997). Lewin et al performed echocardiograms on 278 first degree relatives of
113 probands with a diagnosis of AS, BAV, CoA, HLHS or aortic hypoplasia with mitral
valve atresia and found 21 of 278 (7.5%) to have aortic valve anomalies (Lewin et al.,
2004). Finally, Cripe at al performed echocardiograms on 259 first degree relatives of 50
probands with BAV and found 24 of 259 (9.3%) to have BAV (Cripe, et al., 2004). Using
information on more than 800 relative pairs, Cripe et al found BAV to be strongly
determined by additive genetic effects with a heritability estimate of 89% (2004).
Environmental risk factors
It is generally believed that non-syndromic CHDs occur as a combination of genes
and environment, meaning that non-genetic risk factors also exist for CHDs.
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Characterizing the non-genetic risk factors for CHDs has, however, been challenging and
for many potential risk factors the current evidence linking them to CHDs is limited or
inconclusive (Jenkins et al., 2007). However, there are some risk factors that are wellestablished causes for CHDs, such as maternal pre-gestational diabetes and maternal use of
retinoic acid. Other potential risk factors include maternal obesity and low maternal folate
status. As the prevalence of these latter two factors has changed substantially over the last
20 years, it is possible that recurrence risks estimated from previous time periods may not
provide accurate risks for contemporary populations. For example, if maternal obesity
accounts for an increasing proportion of CHDs, the relative importance of genetic risk
factors may be on the decline.
Folic Acid
In 1992, the Centers for Disease Control made a recommendation that “all women
of childbearing age in the United States who are capable of becoming pregnant should
consume 0.4mg of folic acid per day…” ("Recommendations for the use of folic acid to
reduce the number of cases of spina bifida and other neural tube defects," 1992). Four
years later, the U.S. Food and Drug Administration’s (FDA) final rule on folic acid
fortification was published and implemented nationwide in 1998. The final rule states:
…based on the totality of the publicly available scientific evidence, there is significant
scientific agreement among qualified experts that, among women of childbearing age
in the general U.S. population, maintaining adequate folate intake, particularly during
the periconceptional interval, may reduce the risk of a neural tube birth defectaffected pregnancy. (Kessler, 1996)
This rule created near ubiquitous exposure to folic acid in the U.S.; it is now found in items
such as pasta, rice, and cereals.
Studies conducted on periconceptional folic acid supplementation and on postfortification populations have shown ~25% reduction in the prevalence of any CHD as well
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as specific subgroups of CHDs including conotruncal defects, ventricular septal defects,
and possibly CoA (Botto, Mulinare, & Erickson, 2000; Canfield et al., 2005; Ionescu-Ittu,
Marelli, Mackie, & Pilote, 2009; van Beynum et al., 2010). While the findings of folic acid
conferring a possible protective effect for CHDs are encouraging, they are not conclusive
given mixed results in a limited number of studies (Jenkins, et al., 2007).
Maternal Conditions
Maternal factors that have increased in prevalence in recent years include obesity and
type II diabetes in the United States. According to the National Health and Nutrition
Examination Survey (NHANES), obesity has increased 37% while diabetes has increased
60% since 1990.
Diabetes
Maternal pre-gestational diabetes is known to cause multiple congenital anomalies
and have a teratogenic effect on the cardiovascular system with a reported relative risk of
CHD of 1.7-4.0 (Becerra, Khoury, Cordero, & Erickson, 1990; Ferencz, Rubin, McCarter,
& Clark, 1990; Mills et al., 1988; Mitchell, Sellmann, Westphal, & Park, 1971; Pedersen,
Tygstrup, & Pedersen, 1964; Rowland, Hubbell, & Nadas, 1973; Wren, Birrell, &
Hawthorne, 2003). The most commonly reported defects are laterality defects (e.g.
heterotaxy, situs inversus), conotruncal defects and less commonly, some LSLs (Becerra, et
al., 1990; Ferencz, et al., 1997; Rowland, et al., 1973; Wren, et al., 2003).
Obesity
Significant associations between CHDs and maternal body mass index (BMI), which
is defined as weight in kilograms divided by the square of height in meters, have been
found in many studies. These studies have shown significant increases in the occurrence of
any heart defect in children of overweight (BMI 25-<30 kg/m2), obese (BMI 30-35 kg/m2),
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and severely obese (BMI >35 kg/m2) mothers (Cedergren & Kallen, 2003; Gilboa et al.,
2010; Watkins, Rasmussen, Honein, Botto, & Moore, 2003) (Table 4). Further, Gilboa, et.
al. (2010) found a significant increase in the occurrence of LSLs as a group, as well as a
specific increase in HLHS, in infants of obese mothers.
Table 4. Risk of CHD in children of overweight and obese mothers
Defect(s)
Studied

Overweight
(BMI 25-29.9)

Obese
(BMI 30-35)

Severely Obese
(BMI >35)

OR (95% CI)

OR (95% CI)

Watkins et al,
2003

All CHD

OR (95% CI)
2.0 (1.2-3.1)

Cedergren and
Kallen, 2003

All CHD

1.03 (0.96-1.11)

1.18 (1.09-1.27)

1.41 (1.22-1.64)

HLHS

1.41 (0.90-2.21)

All CHD

1.16 (1.05-1.29)

1.15 (1.00-1.32)

1.31 (1.11-1.56)

1.14 (0.94-1.40)

1.34 (1.03-1.73)

0.85 (0.58-1.26)

1.27 (0.94-1.73)

1.51 (1.03-2.22)

1.21 (0.72-2.06)

Gilboa et al,
2010

LSL

LSL
HLHS

3.3 (1.6-6.7)

Current recurrence risk estimates for LSLs, for relatives other than siblings, are
based on data collected on all types of CHDs and published more than 20 years ago.
Utilizing these same data, recurrence risk estimates were generated for siblings of probands
with specific LSLs. There is evidence to show that CHDs are anatomically, clinically,
epidemiologically and developmentally heterogeneous. Further, potential risk factors for
CHD, such as maternal obesity and maternal folate status, have changed over the past 20
years. Finally, not all CHDs are clinically significant and failure to include sub-clinical
findings will underestimate recurrence risks. Therefore, it is prudent to reassess the risk
estimates for left-sided lesions in a contemporary population with the inclusion of subclinical findings.
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MATERIALS AND METHODS
IRB Approval
This study was reviewed and approved by the Institutional Review Boards for the
Protection of Human Subjects at the University of Texas Health Science Center (HSC-MS10-0469) and The Children’s Hospital of Philadelphia (IRB #1995-1029).
Study Population
This study is based on data from the families of 757 probands recruited between
1997 and 2007 from the Cardiac Center at The Children’s Hospital of Philadelphia. Study
probands were comprised of those with LSLs, including HLHS, CoA, AS/BAV, and
isolated mitral valve anomalies. Males and females of any racial/ethnic group were eligible
to participate in the study. Patients with maligned atrioventricular canal defects or double
outlet right ventricle with mitral valve atresia and those with a recognized genetic syndrome
or chromosome anomaly, including those with Turner syndrome, were excluded from this
study.
Data Collection
Medical records, including, when necessary, original imaging studies were reviewed
to confirm the cardiac diagnosis. In addition, a brief in-person medical interview, usually
with the mother of the proband, that included a three-generation pedigree was completed by
a genetic counselor at The Children’s Hospital of Philadelphia. Data collected as part of the
pedigree included whether each relative had a congenital heart defect (CHD) and, when
available, the specific type of CHD.
One or both parents of 134 probands underwent echocardiography at the Cardiac
Center at The Children’s Hospital of Philadelphia. Standard parasternal short and long axis
views were completed to define aortic valve anatomy and function. Both 2D imaging as
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well as color, pulse wave and continuous wave Doppler analysis was performed to: (1)
define aortic valve anatomy, (2) assess aortic valve leaflet excursion or thickness, (3) detect
turbulent and/or accelerated flow, and (4) detect aortic valve insufficiency. A single
pediatric cardiologist specializing in echocardiography reviewed and characterized all
studies for: (1) the ability to interpret the study, (2) the presence of a tri-, bi or unicuspid
aortic valve, (3) the presence of aortic valve stenosis as defined by thickened leaflets,
limited leaflet excursion, turbulent antegrade flow, and/or accelerated antegrade flow, and
(4) the presence of aortic valve insufficiency. Results were summarized as normal or
abnormal.
Statistical Analysis
The characteristics of the probands were summarized using counts and proportions.
Precurrence and recurrence risks were calculated as the proportion of relatives of a
particular type that had any type of CHD. Pre/recurrence risks were calculated separately
for parents, siblings, second (aunts/uncles) and third (cousins) degree relatives, and within
subgroups of these relatives defined by the sex of the proband, sex of the relative or the
proband’s lesion. For parents, precurrence risks were initially calculated counting as
affected only those parents reported as affected in the pedigree and then including as
affected both those reported by family history and those identified by echocardiography.
Pre/recurrence risks were estimated as binomial proportions and exact 95% confidence
intervals were calculated using an online Java script calculator
(http://statpages.org/confint.html). Risks to different groups of relatives (e.g. mothers and
fathers) were compared using odds ratios and their associated 95% confidence intervals.
Concordance rates were calculated for affected proband-relative pairs, separately for each
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type of relative (i.e. parent, sib, aunt/uncle, cousin). Concordance rates for the same LSL
and for a different LSL were estimated. Unless otherwise noted, all statistical analyses
were conducted using SAS version 9.2.
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RESULTS
Characteristics of the study probands are
presented in Table 5. Briefly, the majority of the
probands were White (85%) and there was a
predominance of males (65%). Approximately,
40% of the probands had HLHS, 35% had CoA,
23% had AS/BAV and the remainder had isolated
mitral valve abnormalities or HLHS variants.
Pre/recurrence risks, i.e., the risk of a

Table 5. Characteristics of the study
probands and families
Proband Gender
Male
Female
Proband CHD
HLHS
CoA
AS/BAV
Other
Proband Ethnicity
White
Black
Other

493 (65%)
264 (35%)
299 (39%)
263 (35%)
171 (23%)
25 (3%)
644 (85%)
63 (8%)
51 (7%)

CHD to relatives born before the study proband or the risk to relatives born after the
proband, for mothers, fathers, brothers, sisters, maternal aunts/uncles, paternal aunts/uncles,
maternal cousins and paternal cousins of 757 LSL probands are summarized in Table 6.
Based on the family history data, the overall risk of any CHD among the parents of
probands was 1.67% (95% CI: 1.08%-2.35%), and was higher for fathers (1.86%, 95% CI:
1.02%-3.10%) than mothers (1.21%, 95% CI: 0.55%-2.28%). The risk to fathers was also
higher than the risk to mothers for each of the three major lesion categories: HLHS (1.99%
versus 1.36%), CoA (1.53% versus 0.78%), and AS/BAV (1.81% versus 1.19%). For both
mothers and fathers, risk varied based on the LSL phenotype of the child, with the highest
risk observed for mothers and fathers of probands with HLHS (1.36% and 1.99%,
respectively).
The overall risk to siblings was markedly higher than that to parents (5.13%, 95%
CI: 3.76%-6.83%). The overall risk to brothers (6.64%, 95% CI: 4.52%-9.34%) was
approximately twice that of sisters (3.46%, 95% CI: 1.90%-5.73%). Further, the risk to
brothers exceeded that to sisters for each of the three major categories of LSLs in the
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proband: HLHS (8.33% versus 2.31%), CoA (5.73% versus 2.37%), and AS/BAV (6.43%
versus 5.21%). For both brothers and sisters, risk varied based on the LSL phenotype of the
proband. Similar to parents, brothers of proband with HLHS had the highest risk (8.33%,
95% CI: 4.38%-14.1%). In contrast, sisters of probands with AS/BAV had the highest risk
(5.21%, 95% CI: 1.17%-11.74%).
Among avuncular relatives, the overall risk was 0.51% (95% CI: 0.30%-0.82%).
Overall, and within categories defined by the proband’s lesion, risks were generally higher
for paternal as compared to maternal aunts/uncles, however they were equal for CoA (Table
6). For both maternal and paternal aunts/uncles the risk varied based on LSL phenotype of
the proband with the highest risk observed for paternal aunts/uncles of probands with both
HLHS (0.78%, 95% CI: 0.25%-1.8%) and AS/BAV (0.78%, 95% CI: 0.16%-2.27%). The
highest risk for maternal aunts/uncles was observed for probands with AS/BAV (0.49%,
0.06-1.77).
Among first cousins, the overall risk was 0.74% (95% CI: 0.49%-1.06%) and was
higher for paternal first cousins (0.90%, 0.54-1.42) than maternal first cousins (0.57%,
0.28-1.01). The risk to paternal cousins was also higher than maternal cousins for the three
major lesion categories: HLHS (1.04% versus 0.70%), CoA (0.29% versus 0.27%), and
AS/BAV (1.46% versus 0.86%). For both maternal and paternal cousins, risk varied based
on LSL phenotype of the proband, with the highest risk observed for maternal and paternal
cousins of probands with AS/BAV (0.86% and 1.46%, respectively).
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Table 6. Pre/recurrence risks by relationship and subdivided by proband lesion
Relationship to
Proband
HLHS
n=299

Pre/Recurrence risk by proband lesion
n/Total
% (95%CI)
CoA
AS/BAV
n=263
n=171

Total**
N=758

Parent
Fam History only
Fam Hx + echo

10/596
1.68 (0.81-306)
19/596
3.19 (1.93-4.93)

6/517
1.16 (0.43-2.51)
14/517
2.71 (1.49-4.50)

5/334
1.50 (0.49-3.46)
8/334
2.40 (1.04-4.66)

25/1496
1.67 (1.08-2.35)
43/1496
2.87 (2.09-3.85)

4/295
1.36 (0.37-3.43)
5/295
1.69 (0.55-3.91)

2/256
0.78 (0.09-2.79)
7/256
2.73 (1.11-5.55)

2/168
1.19 (0.14-4.23)
3/168
1.79 (0.37-5.13)

9/744
1.21 (0.55-2.28)
16/744
2.15 (1.23-3.47)

Mother
Fam History only
Fam Hx + echo
Father
6/301
4/261
3/166
14/752
1.99 (0.74-4.26)
1.53 (0.42-3.88)
1.81 (0.37-5.19)
1.86 (1.02-3.10)
14/301
7/261
5/166
27/752
Fam Hx + echo
4.65 (2.57-7.68)
2.68 (1.08-5.45)
3.01 (0.99-6.89)
3.59 (2.38-5.18)
15/274
13/326
14/236
44/857
Sibling
5.47 (3.10-8.87)
3.99 (2.14-9.72)
5.93 (3.28-9.75)
5.13 (3.76-6.83)
3/130
4/169
5/96
14/405
Sister
2.31 (0.48-6.60)
2.37 (0.65-5.95)
5.21 (1.17-11.74)
3.46 (1.90-5.73)
12/144
9/157
9/140
30/452
Brother
8.33 (4.38-14.1)
5.73 (2.65-10.6)
6.43 (2.98-11.85)
6.64 (4.52-9.34)
7/1211
4/1203
5/789
17/3302
Second Degree
0.58 (0.23-1.19)
0.33 (0.09-0.85)
0.63 (0.21-1.47)
0.51 (0.30-0.82)
2/566
2/599
2/405
6/1621
Mat. aunt/uncle
0.35 (0.04-1.27)
0.33 (0.04-1.20)
0.49 (0.06-1.77)
0.37 (0.14-0.80)
5/645
2/604
3/384
11/1681
Pat. aunt/uncle
0.78 (0.25-1.8)
0.33 (0.04-1.19)
0.78 (0.16-2.27)
0.65 (0.33-1.17)
12/1344
4/1421
12/1059
29/3934
Third Degree
0.89 (0.46-1.55)
0.28 (0.08-0.72)
1.13 (0.59-1.97)
0.74 (0.49-1.06)
4/573
2/731
5/581
11/1940
Mat. first cousin
0.70 (0.19-1.78)
0.27 (0.03-0.98)
0.86 (0.28-2.0)
0.57 (0.28-1.01)
8/771
2/690
7/478
18/1994
Pat. first cousin
1.04 (0.45-2.03)
0.29 (0.04-1.04)
1.46 (0.59-2.99)
0.90 (0.54-1.42)
**
N may be greater than the sum of three subtypes because other miscellaneous types of defects have not been
subdivided.
Fam History only
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Pre/recurrence risks were also estimated separately for the relatives of male and
female probands for first degree relatives (Table 7) as well as second and third degree
relatives (Table 8). Risks were not consistently associated with the sex of the proband (e.g.
risks were higher for mothers of male probands as compared to female probands, whereas
the opposite was true for fathers). The high risks to brothers of male probands (7.87%,
95% CI: 5.11%-11.48%) and in particular the brothers of male probands with HLHS
(11.8%, 95% CI: 6.06%-20.18%) are, however, of note.
Table 9 summarizes the concordance rates for proband-affected relative pairs.
Among affected parents, 65% (n=15) had a LSL and among these parents 47% (7/15) had
the same lesion as their affected child. Concordance rates for AS/BAV were particularly
high with all six of the affected parents of a proband with AS/BAV also having AS/BAV.
Among affected sibs, 70% (n=31) had a LSL and among these sibs 55% (17/31) had the
same lesion as the proband. Similar to parents, concordance rates for AS/BAV were
particularly high with 10 of the 14 (71%) affected sibs of a proband with AS/BAV also
having this condition. Concordance rates for second (24%) and third (21%) degree
relatives were lower than those observed for first-degree relatives. The relatively small
number of affected relative pairs in these categories precluded meaningful assessment of
concordance for specific lesion types. The specific CHD observed in affected relatives who
did not have a LSL are summarized in Table 10.
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Table 7. Pre/recurrence risks by relationship subdivided by both proband gender and proband lesion
Pre/Recurrence risk by proband gender and lesion, n/Total % (95%CI)
Relationship to
Proband

HLHS
Male
(n=188)

CoA
Female
(n=110)

Male
(n=161)

Total

AS/BAV
Female
(n=102)

Male
(n=132)

Female
(n=39)

Male
(n=493)

Female
(264)

Parent
Fam History only
Fam Hx + echo

6/375
1.60 (0.59-3.45)
12/375
3.20 (1.66-5.52)

4/219
1.83 (0.50-4.61)
7/219
3.20 (1.29-6.47)

2/317
0.63 (0.08-2.26)
8/317
2.52 (1.10-4.91)

4/200
2.00 (0.55-5.04)
6/200
3.00 (1.11-6.41)

5/258
1.94 (0.63-4.46)
7/258
2.71 (1.10-5.51)

1/76
1.32 (0.03-7.11)
1/76
1.32 (0.03-7.11)

14/974
1.44 (0.79-2.40)
27/974
2.77 (1.83-4.01)

9/520
1.73 (0.79-3.26)
15/520
2.88 (1.62-4.71)

2/185
1.08 (0.13-3.85)
3/185
1.62 (0.34-4.67)

2/109
1.83 (0.22-6.47)
2/109
1.83 (0.22-6.47)

1/157
0.64 (0.02-3.50)
5/157
3.18 (1.04-7.28)

1/99
1.01 (0.03-5.50)
2/99
2.02 (0.25-7.11)

2/130
1.54 (0.19-5.45)
2/130
1.54 (0.19-5.45)

1/38
2.63 (0.07-13.8)
1/38
2.63 (0.07-13.8)

6/484
1.24 (0.46-2.68)
11/484
2.27 (1.14-4.03)

3/259
1.16 (0.24-3.35)
5/259
1.93 (0.63-4.45)

4/190
2.11 (0.58-5.30)
9/190
4.74 (2.19-8.80)
13/168
7.74 (4.18-12.87)
11/93
11.83 (6.06-20.18)
2/75
2.67 (0.32-9.30)

2/110
1.82 (0.22-6.41)
5/110
4.55 (1.49-10.29)
2/106
1.89 (0.23-6.65)
1/51
1.96 (0.05-10.45)
1/55
1.82 (0.05-9.72)

1/160
0.63 (0.02-3.43)
3/160
1.88 (0.39-5.38)
7/207
3.38 (1.37-6.84)
6/100
6.00 (2.23-12.60)
1/107
0.93 (0.02-5.10)

3/101
2.97 (0.62-8.44)
4/101
3.96 (1.09-9.83)
6/119
5.04 (1.87-10.65)
3/57
5.26 (1.10-14.62)
3/62
4.84 (1.01-13.5)

3/128
2.34 (0.49-6.70)
5/128
3.91 (1.28-8.88)
11/172
6.40 (3.24-11.15)
7/107
6.54 (2.67-13.02)
4/65
6.15 (1.70-15.01)

0/38
0.0
0/38
0.0
3/64
4.69 (0.98-13.1)
2/33
6.06 (0.74-20.2)
1/31
3.23 (0.08-16.7)

8/490
1.63 (0.71-3.19)
17/490
3.47 (2.03-5.50)
31/555
5.58 (3.83-7.83)
24/305
7.87 (5.11-11.48)
7/250
2.80 (1.13-5.68)

6/261
2.30 (0.85-4.94)
10/261
3.83 (1.85-6.93)
13/302
4.30 (2.31-7.25)
6/147
4.08 (1.51-8.67)
7/155
4.52 (1.83-9.08)

Mother
Fam History only
Fam Hx + echo
Father
Fam History only
Fam Hx + echo
Sibling
Brother
Sister
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Table 8. Pre/recurrence risks by relationship
subdivided by proband gender
Relationship to
Proband
Second Degree*
Mat. aunt/uncle
Pat. aunt/uncle
Third Degree*
Mat. first cousin
Pat. first cousin

Pre/Recurrence risk by proband
gender, n/Total % (95%CI)
Male
Female
11/2120
6/1178
0.52 (0.26-0.93)
0.51 (0.19-1.11)
4/1033
2/587
0.39 (0.11-0.99)
0.34 (0.04-1.23)
7/1087
4/591
0.64 (0.26-1.32)
0.68 (0.18-1.72)
21/2546
8/1385
0.82 (0.51-1.26)
0.58 (0.25-1.13)
7/1239
4/698
0.56 (0.23-1.16)
0.57 (0.16-1.46)
4/1307
4/687
0.31 (0.08-0.78)
0.58 (0.16-1.48)

*

Defect and sex specific risks were not calculated for second
and third degree relatives due to small numbers within most
categories

Table 9. Concordance rates for affected relative pairs with the same LSL, different LSLs, or
non-LSL defects
Affected Parent
Proband Diagnosis
HLHS (n=11)
CoA (n=6)
AS/BAV (n=6)
All (n=23)
Affected Sibling
Proband Diagnosis
HLHS (n=15)
CoA (n=15)
AS/BAV (n=14)
All (n=44)
Affected aunt/uncle
Proband Diagnosis
HLHS (n=8)
CoA (n=4)
AS/BAV (n=5)
All (n=17)
Affected cousin
Proband Diagnosis
HLHS (n=12)
CoA (n=4)
AS/BAV (n=12)
All (n=28)

Concordant – same lesion
0
1 (17%)
6 (100%)

Concordant – Different LSL
7 (64%)
1 (17%)
0
15 (65%)

Discordant – not LSL
4 (36%)
4 (66%)
0
8 (35%)

Concordant – same lesion
3 (20%)
4 (27%)
10 (71%)

Concordant – Different LSL
5 (33%)
7 (47%)
2 (14%)
31 (70%)

Discordant – not LSL
7 (47%)
4 (27%)
2 (14%)
13 (30%)

Concordant – same lesion
0
1 (25%)
0

Concordant – Different LSL
3 (37%)
0
0
4 (24%)

Discordant – not LSL
5 (63%)
3 (75%)
5 (100%)
13 (76%)

Concordant – same lesion
2 (17%)
0
0

Concordant – Different LSL
2 (17%)
0
2 (17%)
6 (21%)

Discordant – not LSL
8 (66%)
4 (100%)
10 (83%)
22 (79%)
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Table 10. Diagnoses for discordant proband-affected
relative pairs
Affected Parent – Discordant (n=8)
Proband Diagnosis
Discordant Relative Diagnosis
VSD; L-TGA; ASD; other
HLHS (n=4)
PDA; TOF; unknown (2)
CoA (n=4)
AS/BAV (n=0)
Affected Sibling – Discordant (n=13)
Proband Diagnosis
Discordant Relative Diagnosis
VSD (4); ASD; DORV; PS
HLHS (n=7)
IAA; PDA; VSD; AVCD
CoA (n=4)
other; unspecified hole in heart
AS/BAV (n=2)
Affected aunt/uncle – Discordant (n=13)
Proband Diagnosis
Discordant Relative Diagnosis
ASD; unspecified hole in heart (4); unknown
HLHS (n=5)
ASD; unspecified hole in heart; unknown
CoA (n=3)
ASD; VSD; unspecified hole in heart (3)
AS/BAV (n=5)
Affected cousin – Discordant (n=22)
Proband Diagnosis
Discordant Relative Diagnosis
PS; unspecified hole in heart (4); unknown (3)
HLHS (n=8)
VSD (2); pulmonary artery anomaly; unknown
CoA (n=4)
TGA; PS; AAA; unspecified hole in heart (4);
AS/BAV (n=10)
unknown (2); other
[VSD: ventricular septal defect; ASD: atrial septal defect; PDA: patent
ductus arteriosis; TOF: Tetralogy of Fallot; L-TGA: transposition of the
great arteries (left); AVCD: atrioventricular canal defect; IAA: interrupted
aortic arch; DORV: double outlet right ventricle; PS: pulmonary stenosis;
AAA: abdominal aortic aneurysm]

Table 11. Echocardiography findings among parents of probands with LSLs
Total
N (%)
Mother

101 (50%)

Father

101 (50%)

Total

202

Normal
N
% (95% CI)
94
93.1 (86.2-97.2)
88
87.1 (79.0-93.0)
186
92.1 (87.5-95.4)

Abnormal
N
% (95% CI)
7
6.9 (2.83-13.8)
13
12.9 (7.03-21.0)
20
9.9 (6.15-14.9)

91
91 (83.6-95.8)
54
87 (76.2-94.3)
23
88.5 (69.9-97.6)
5
100
9
100

9
9 (4.20-16.4)
8
13 (5.74-23.9)
3
11.5 (2.45-30.2)
0

Proband Diagnosis
HLHS

100 (50%)

CoA

62 (31%)

AS/BAV

26 (13%)

Other

5 (2%)

Unknown

9 (4%)

0
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The apparently unaffected parents of 134 probands were evaluated by
echocardiography. The distribution of LSLs among these probands (HLHS 50%, CoA 31%,
AS/BAV 13%, Other/Unknown 6%) was similar to that of the full study sample (Table 5),
although the proportion of probands with HLHS was somewhat higher (50% versus 39%).
Both parents were evaluated in 68 (50%) families while the mother only was evaluated in 33
(25%) and the father only in 33 (25%) cases.
Among the parents evaluated by echocardiography, the overall prevalence of
previously unrecognized CHD, such as BAV, was 9.9% (Table 11). The prevalence of
previously unrecognized CHD was 12.9% (7.03-21.0) among fathers and 6.9% (2.83-13.8)
among mothers. Fathers were nearly two times more likely to have previously unrecognized
CHD compared to mothers (OR=1.98, 95% CI 0.76-5.20), although this result is not
significant likely due to a smaller sample size. The prevalence of unrecognized CHD also
varied as a function of the specific LSL phenotype of the proband, ranging from 0% for
parents of probands with other/unknown lesions to 11.5% (2.45-30.2) among the parents of
probands with AS/BAV.
When parents identified as having CHD by echo were included in the numerator for
the precurrence risk estimates, risks increased in almost all categories (Tables 6 and 7). The
inclusion of these data resulted in the greatest increase in the risk estimate for mothers of
probands with CoA (0.78% to 2.73%) and fathers of probands with HLHS (1.99% to
4.65%).
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DISCUSSION
Currently, recurrence risks for left-sided cardiac lesions are based on combined data
from multiple studies conducted 20 to 40 years ago (Nora, et al., 1991). These data support
familial clustering of CHDs with a sibling recurrence of 2-3%. Offspring recurrence risks
were also found to be elevated (4-18%) and to vary based on the sex of the affected parent.
These recurrence risks are now the published numbers found in Harper’s Practical Genetic
Counseling, a reference book well known to those who practice genetic counseling (Harper,
2004). Given that many environmental (e.g. maternal consumption of folic acid) and
maternal conditions (e.g. maternal diabetes and obesity), as well as diagnostic capabilities,
have changed over the past twenty years, it is prudent to reassess the CHD recurrence risks
currently used in clinical practice. Increased recognition of distinct subgroups of CHDs,
which may each have different recurrence risks, makes reassessment of risk estimates for the
individual groups sensible.
In this study, data collected from a clinic population at The Children’s Hospital of
Philadelphia were used to assess pre/recurrence risks for first (parents, siblings), second
(aunts/uncles) and third (cousin) degree relatives of probands with LSLs (e.g. HLHS, CoA,
and AS/BAV). Family history data were analyzed alone and with the inclusion of
echocardiography data collected on parents of a subset of the probands. Concordance rates
for proband-affected relative pairs were also examined.
Practical Genetic Counseling (Harper, 2004) provides risk estimates for overall
congenital heart disease. These are the general numbers used when counseling regarding
recurrence for CHD and when specific details of the proband’s diagnosis are not available.

30

In a comparison of these estimates to those found in this study, the sibling risk estimate is
higher in our LSL cohort than for all CHDs (Table 12). The risk estimates for second and
third degree relatives found in this study and those for all CHDs are fairly comparable.
However, in the present study, the risk to second degree relatives is lower than third degree
relatives. While this may seem counterintuitive, it is likely a reflection of a number of
factors including, advances in diagnostic capabilities and modern standards of care for
evaluating murmurs in children, improved reporting of cousins as compared to older patients
such as avuncular relatives, and older relatives who died in infancy may never have received
a diagnosis. This finding was also reported by Loffredo, et al (2004) in a LSL cohort.
Table 12. Comparison of approximate recurrence risks
for all CHD versus LSL only
Risk, %
Risk, % (95%CI)
Relation to
Harper, 2004
Present study
Proband
All CHD
LSL only
2-3
5.0 (3.76-6.83)
Sibling
1-2
0.5 (0.30-0.82)
Second degree
*
<1
0.7 (0.49-1.06)
Third degree
*

According to Harper, data are inadequate.

In addition to providing overall CHD risk estimates for first, second and third degree
relatives, Practical Genetic Counseling (Harper, 2004) also provides estimates of the risk to
sibs of probands with specific LSLs. We found the pre/recurrence risks for any CHD when
the proband is affected with HLHS, CoA or AS/BAV to be higher than risks quoted in
Harper (Table 13). One possible explanation for this apparent increase in the risk to sibs of
LSL probands is improvements in the diagnosis of CHD over time. Progress in
echocardiography over the past 20 years has made diagnosis easier and more precise and so
could account for part of the increase in risk estimates. Another possible explanation is the
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increasing prevalence of potential maternal risk factors including pre-gestational diabetes
and obesity, which would likely represent shared exposures for siblings. The incidence of
these conditions has increased 37% and 60%, respectively since 1990 (Cowie et al., 2006;
Flegal, Carroll, Kuczmarski, & Johnson, 1998; Ogden & Carroll, 2010; "Vital and health
statistics. Current estimates from the National Health Interview Survey, 1988," 1989).

Table 13. Comparison of approximate recurrence risks for
sibs of probands with left-sided cardiac lesions
Proband Defect
HLHS
CoA
AS/BAV

Risk, %
Harper, 2004*
3
2
2

Risk, % (95%CI)
Present study
5.5 (3.1-8.9)
4.0 (2.1-6.7)
6.0 (3.3-9.8)

*Based on multiple studies collated by Nora JJ, Berg K, Nora AH
(1991)

Among first-degree relatives in this study, the risk to male relatives (i.e. fathers and
brothers) was increased relative to their female counterparts. This finding was also reported
by Lewin, et al. (2004) in a LSL cohort. Estimates of risk to second and third degree
relatives by sex of the relative were not determined, given the small number of affected
relatives in these categories. When risk estimates were stratified based on the sex of the
proband there was no clear pattern of increased risk for the relatives of either males or
females. Among second and third degree relatives there was, however, a tendency for risks
to be higher in paternal relatives as compared to their maternal counterparts. Previous
studies have not commented on the maternal/paternal relative pre/recurrence risk.
Further subdividing the risk estimates, we found the pre/recurrence risk for brothers
(7%) to be higher than sisters (3%) for all LSLs. In general, fathers of probands with LSLs
were also more likely to be affected (4%) than mothers of probands (2%). However, the
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precurrence risks were almost equal when the proband had CoA. The pre/recurrence risks
for aunts/uncles and cousins were less than 1% for all LSLs and the division of these groups
based on maternal or paternal lineage did not make a clear difference.
Subgroup analysis was also performed based on the gender of the proband and
specific LSL. In general, the sex of the proband did not appear to influence the precurrence
risks in parents. However, in siblings the pre/recurrence risk for brothers of male probands
was almost double (~8%) that for brothers of female probands (4%). Much of this
difference is comprised of the almost 12% pre/recurrence risk found for brothers of males
with HLHS. Prior studies have not examined recurrence risk based on sex and lesion of the
proband together. Of note, as the groups continued to be subdivided the numbers of affected
relatives became quite small and therefore, these risk estimates are deemed imprecise.
This study also aimed to estimate the concordance rate among proband-affected
relative pairs. Among affected parents and siblings the concordance rates were 65% and
70%, respectively. For each group, of those that were concordant, approximately half had
the same lesion as the proband. The fact that there are no proband-affected parent pairs
concordant for HLHS is not surprising given that individuals with HLHS have historically
not survived to reach child-bearing age. In second and third degree relatives the
concordance rate is lower than first degree relatives. Decreasing concordance with
increasing degree of kinship is consistent with previous studies. Based on our findings,
AS/BAV has the highest rate of concordance among the proband-affected first-degree
relative pairs suggesting a largely genetic component, as found in previous studies (Cripe, et
al., 2004). In those relatives that were discordant, the most common anomalies seen were
VSD, ASD, and unspecified hole in heart. This is consistent with the general population
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risks for CHD in which VSD and ASD are the most common CHDs, with a population
prevalence of 0.5% and 0.1%, respectively (Drugan, 2006). Together, these findings
suggest, based primarily on first-degree relatives, that LSLs are more closely related to each
other than other CHDs.
Finally, this study aimed to estimate the proportion of parents of probands with a
LSL who had a previously unrecognized aortic valve abnormality and were subsequently
diagnosed by echocardiography. Approximately 10% of parents had abnormal
echocardiograms showing bicuspid or thickened aortic valve or aortic regurgitation. This
finding is similar to other studies that have identified aortic valve abnormalities by
echocardiography in 7.5% - 12% of first degree relatives of LSL probands (Brenner, et al.,
1989; Cripe, et al., 2004; Huntington, et al., 1997; Lewin, et al., 2004). Abnormal findings
were more common in fathers (13%) than in mothers (7%). This may be accounted for by
the male predominance of both CoA (M:F 2:1) and AS/BAV (M:F 2:1) in the general
population (Nora, et al., 1991). The current study, comparable to Lewin, et al., uses a
sample from the complete spectrum of LSLs, whereas others used a subset of proband LSLs
(Brenner, et al., 1989; Huntington, et al., 1997; Lewin, et al., 2004; Loffredo, et al., 2004).
Lewin, et al. performed echocardiograms on 282 first-degree relatives (parents and siblings)
of probands with LSLs and found 21 (7.55%) individuals with aortic valve anomalies
(2004). They found that the proportion of left heart anomalies for mothers, fathers, sisters,
and brothers was not significantly different when compared by proband diagnosis or gender.
We have confirmed the excess occurrence of BAV in first-degree relatives of probands with
HLHS as well as other left-sided lesions.
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BAV is often considered a benign lesion early in life, but complications of BAV
including aortic stenosis, aortic regurgitation, and aortic dilation result in morbidity later in
life (Ward, 2000). These complications should be monitored and interventions made as
needed, making the early detection of BAV paramount and supporting previous
recommendations to screen first degree relatives of probands with left-sided lesions
(Huntington, et al., 1997).
Based on the 10% detection of valve abnormalities by echocardiography data, it is
evident these studies increase risk estimates. However, our risk estimates are still an
underestimate given that echocardiograms were only performed on a subset of parents.
As with all studies, this study had some limitations including the use of families
ascertained through a single large referral center. Since such centers may serve a nonrandom subset of all LSL cases, this population may be enriched for more severe cardiac
defects. Consequently, the pre/recurrence risks estimated from this population may not be
generalizable to the broader population. In addition, the family history data were based on
the report of the proband’s parents. Hence, the diagnosis reported for affected relatives may
not be accurate and some affected relatives may have not been identified. Further, given the
timeframe of this study, some of the relatives would likely have been conceived prior to
folic acid fortification. If such fortification is associated with a change in familial
pre/recurrence risks, these estimates may not be reflective of the contemporary population.
This study also had several strengths including a relatively large sample size, clinical
confirmation of the diagnosis in probands and the classification of apparently unaffected
parents by a single echocardiographer.
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Convincing evidence exists for a substantial genetic component in the left-sided
lesions, HLHS, CoA and AS/BAV. The results of this study are generally consistent with
previous studies aiming to determine the prevalence of BAV in first-degree relatives of
probands with left-sided lesions. Currently, no protocol exists for the examination of
relatives of probands with LSLs; however, on the basis of these results and those of previous
studies, echocardiographic screening of first-degree relatives of LSL probands is warranted.
Pre/recurrence risks in this study were found to be overall higher than those used in current
practice. Future population based studies can help to confirm or refute the findings of this
study. While these numbers may not significantly change counseling methods, using these
data combined with future population based studies can provide relevant updates to
pre/recurrence risk estimates for left-sided cardiac lesions.
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